Skip to main navigation Skip to search Skip to main content

COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity

  • Laura Gragnani
  • , Marcella Visentini
  • , Serena Lorini
  • , Stefano Angelo Santini
  • , Gianfranco Lauletta
  • , Cesare Mazzaro
  • , Teresa Urraro
  • , Luca Quartuccio
  • , Fabio Cacciapaglia
  • , Piero Ruscitti
  • , Antonio Tavoni
  • , Silvia Marri
  • , Giuseppina Cusano
  • , Luisa Petraccia
  • , Caterina Naclerio
  • , Elena Treppo
  • , Giulia Del Frate
  • , Ilenia Di Cola
  • , Vincenzo Raimondo
  • , Daniela Scorpiniti
  • Monica Monti, Lorenzo Puccetti, Giusy Elia, Poupak Fallahi, Stefania Basili, Salvatore Scarpato, Florenzo Iannone, Milvia Casato, Alessandro Antonelli, Anna Linda Zignego, Clodoveo Ferri
  • University of Florence
  • University “La Sapienza” of Rome
  • University of Bari
  • IRCCS Centro di Riferimento Oncologico - Aviano PN
  • M. Scarlato Hospital
  • University of Udine
  • University of L'Aquila
  • University of Pisa
  • Rheumatology Clinic ‘Madonna dello Scoglio’ Cotronei

Research output: Contribution to journalArticle

Abstract

Purpose: Mixed cryoglobulinemia syndrome (MCs) is a rare immunoproliferative systemic disorder with cutaneous and multiple organ involvement. Our multicenter survey study aimed to investigate the prevalence and outcome of COVID-19 and the safety and immunogenicity of COVID-19 vaccines in a large MCs series. Methods: The survey included 430 unselected MCs patients (130 M, 300 F; mean age 70 ± 10.96 years) consecutively collected at 11 Italian referral centers. Disease classification, clinico-serological assessment, COVID-19 tests, and vaccination immunogenicity were carried out according to current methodologies. Results: A significantly higher prevalence of COVID-19 was found in MCs patients compared to Italian general population (11.9% vs 8.0%, p < 0.005), and the use of immunomodulators was associated to a higher risk to get infected (p = 0.0166). Moreover, higher mortality rate was recorded in MCs with COVID-19 compared to those without (p < 0.01). Patients’ older age (≥ 60 years) correlated with worse COVID-19 outcomes. The 87% of patients underwent vaccination and 50% a booster dose. Of note, vaccine-related disease flares/worsening were significantly less frequent than those associated to COVID-19 (p = 0.0012). Impaired vaccination immunogenicity was observed in MCs patients compared to controls either after the first vaccination (p = 0.0039) and also after the booster dose (p = 0.05). Finally, some immunomodulators, namely, rituximab and glucocorticoids, hampered the vaccine-induced immunogenicity (p = 0.029). Conclusions: The present survey revealed an increased prevalence and morbidity of COVID-19 in MCs patients, as well an impaired immunogenicity even after booster vaccination with high rate of no response. Therefore, MCs can be included among frail populations at high risk of infection and severe COVID-19 manifestations, suggesting the need of a close monitoring and specific preventive/therapeutical measures during the ongoing pandemic.
Original languageEnglish
Pages (from-to)680-691
Number of pages12
JournalJournal of Clinical Immunology
Volume43
DOIs
Publication statusPublished - 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COVID-19 vaccine
  • SARS-CoV-2
  • cryoglobulinemic vasculitis
  • immunogenicity
  • mixed cryoglobulinemia

Fingerprint

Dive into the research topics of 'COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity'. Together they form a unique fingerprint.

Cite this